Follow The Filings

NVCR Novocure Ltd.

Health Care, filed as NOVOCURE LTD (ORD SHS), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 2.7%
  • $19M

Who owns this now

Largest portfolio weights among holders, up to 2.7% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors 2.7%

Who owns NVCR

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 2.7% Hold 1,280,439 $19M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by NVCR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NVCR insider trades
  • None no insider bought on the open market
  • $596K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Mukund Paravasthu COO
    Sale
    $596K 43,246 shares at $13.77 37% of stake
    Traded Mar 5 Filed Mar 5
    ↗

Also filed in the last 12 months, not counted as buying or selling: 24 stock grants, 24 sales to cover taxes, 10 share withholdings for taxes, and 1 option exercise.

Congress

No member of Congress reported trading NVCR in the last three years. 1 member listed it in 2025 annual reports.

All Congress trades

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
8-K 7.01,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K/A 5.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $509.34M $605.22M $655.35M
Gross profit $381.06M $468.04M $488.47M
Gross margin * 74.8% 77.3% 74.5%
Net income -$207.04M -$168.63M -$136.23M
Net margin * -40.6% -27.9% -20.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.03B $1.11B $0.647B
Total non-current assets $111.72M $134.21M $157.6M
Total assets $1.15B $1.24B $0.804B
Total current liabilities $179.12M $756.38M $223.23M
Total non-current liabilities $604.52M $124.23M $240.63M
Total equity $362.5M $360.18M $340.47M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$73.34M -$26.37M -$49.03M
Cash from investing $184.15M -$140.24M $437.28M
Cash from financing $15.79M $90.32M -$451.34M
Net change in cash $126.73M -$76.47M -$62.7M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.